Clinical trial
A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell…
NCT00042666 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00042666 |
|---|---|
| Title | A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. |
| Official title | A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | LY317615 |
| Enrollment | 55 |
| Start date | Jun 1, 2002 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 6, 2002 |
| Last update posted | Aug 10, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: